Recent Posts
- Final Results Of The First-In-Human Study Of The Amyloid-Reactive Peptide 124I-p5+14, (Iodine[124I] Evuzamitide; AT-01) For The Detection Of Systemic Amyloidosis
- Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis Using iodine (124I) evuzamitide (124I-p5+14) Identifies Organ-Specific Amyloid Regression
- Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
Recent Comments
No comments to show.